Literature DB >> 33404046

No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension.

Estrellita Uijl1, Liwei Ren1, Katrina M Mirabito Colafella2, Richard van Veghel1, Ingrid M Garrelds1, Oliver Domenig3, Marko Poglitsch4, Ivan Zlatev5, Jae B Kim5, Stephen Huang5, Lauren Melton5, Ewout J Hoorn1, Don Foster5, A H Jan Danser1.   

Abstract

Brain renin-angiotensin system (RAS) activation is thought to mediate deoxycorticosterone acetate (DOCA)-salt hypertension, an animal model for human primary hyperaldosteronism. Here, we determined whether brainstem angiotensin II is generated from locally synthesized angiotensinogen and mediates DOCA-salt hypertension. To this end, chronic DOCA-salt-hypertensive rats were treated with liver-directed siRNA targeted to angiotensinogen, the angiotensin II type 1 receptor antagonist valsartan, or the mineralocorticoid receptor antagonist spironolactone (n=6-8/group). We quantified circulating angiotensinogen and renin by enzyme-kinetic assay, tissue angiotensinogen by western blotting, and angiotensin metabolites by LC-MS/MS. In rats without DOCA-salt, circulating angiotensin II was detected in all rats, whereas brainstem angiotensin II was detected in 5 out of 7 rats. DOCA-salt increased mean arterial pressure by 19±1 mmHg and suppressed circulating renin and angiotensin II by >90%, while brainstem angiotensin II became undetectable in 5 out of 7 rats (<6 fmol/g). Gene silencing of liver angiotensinogen using siRNA lowered circulating angiotensinogen by 97±0.3%, and made brainstem angiotensin II undetectable in all rats (P<0.05 vs. non-DOCA-salt), although brainstem angiotensinogen remained intact. As expected for this model, neither siRNA nor valsartan attenuated the hypertensive response to DOCA-salt, whereas spironolactone normalized blood pressure and restored brain angiotensin II together with circulating renin and angiotensin II. In conclusion, despite local synthesis of angiotensinogen in the brain, brain angiotensin II depended on circulating angiotensinogen. That DOCA-salt suppressed circulating and brain angiotensin II in parallel, while spironolactone simultaneously increased brain angiotensin II and lowered blood pressure, indicates that DOCA-salt hypertension is not mediated by brain RAS activation. Copyright 2021 The Author(s).

Entities:  

Keywords:  RNAi therapeutics; angiotensin II; angiotensinogen; brain; mineralocorticoid receptor antagonism; salt-sensitive hypertension

Year:  2021        PMID: 33404046     DOI: 10.1042/CS20201239

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  3 in total

Review 1.  Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.

Authors:  Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 2.  The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts.

Authors:  Carlos M Ferrario; Leanne Groban; Hao Wang; Xuming Sun; Jessica L VonCannon; Kendra N Wright; Sarfaraz Ahmad
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

3.  Conventional Vasopressor and Vasopressor-Sparing Strategies to Counteract the Blood Pressure-Lowering Effect of Small Interfering RNA Targeting Angiotensinogen.

Authors:  Estrellita Uijl; Dien Ye; Liwei Ren; Katrina M Mirabito Colafella; Richard van Veghel; Ingrid M Garrelds; Hong S Lu; Alan Daugherty; Ewout J Hoorn; Paul Nioi; Don Foster; A H Jan Danser
Journal:  J Am Heart Assoc       Date:  2022-07-25       Impact factor: 6.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.